Sanofi SNY

In 2019, Patrick Kron was appointed Chairman of Imerys. He is also Chairman of private equity firm Truffle Capital since November 2016 and Chairman of PKC&I SAS. He started his career in the French Ministry of Industry where he served from 1979 until 1984. He then joined the Pechiney Group where from 1984 until 1988 he held operational responsibilities in one of the Group's most important factories in Greece, becoming manager of the Greek subsidiary. From 1988 to 1993, he occupied several senior operational and financial positions within Pechiney, first managing a group of activities in the processing of aluminium and eventually as President of the Electrometallurgy Division. In 1993, he became a member of the Executive Committee of the Pechiney Group and was appointed Chairman of the Board of the Carbone Lorraine Company, a position he held until 1997. From 1995 to 1997, he ran the Food and Health Care Packaging Sector of Pechiney and held the position of Chief Operating Officer of the American National Can Company in Chicago (USA). From 1998 to 2002, Patrick Kron was Chief Executive Officer of Imerys before joining Alstom in 2002. He was appointed CEO of Alstom, then Chairman and CEO in 2003, a position he held until January 2016, when he created PKC&I. Patrick Kron was awarded the Legion d'honneur in 2004 and is Officer of National Order of Merit since 2007. Patrick Kron is a graduate of Ecole polytechnique and the Paris Ecole des mines. Directorships and appointments outside the Sanofi Group Directorships as of 12/31/2021 Chairman of Imerys Chairman of Truffle Capital SAS (France) Chairman of PKC&I SAS (France) Permanent representative of PKC&I on the Supervisory Board of Segula Technologies Director of Holcim (Switzerland) Director of Viohalco (Belgium).Current directorships and appointments Director of SGS (Switzerland) Past directorships expiring within the last five years In foreign companies ElvalHalcor (Greece) Director of Holcim (Switzerland).

Mr. Jean-Paul Kress, Independent Director. Education and professional experience: Since 2025 Chairman and CEO of Vor Bio 2019-2024 CEO of MorphoSys (acquired by Novartis); 2019-2023 Chairman of the Board of Directors of ERYTECH Pharma; 2018 Chairman and CEO of Syntimmune (acquired by Alexion); 2017-2018 Executive Vice President, International President and Head of Global Therapeutic Operations of Biogen 2015-2017 Member of the Board of Directors of Sarepta Therapeutics; 2015-2017 Senior Vice President, Head of North America at Sanofi Genzyme; 2011-2015 Chairman and CEO at Sanofi Pasteur MSD; 1997-2006 General Manager, Denmark / Various US and EU Roles in Marketing, Commercial Operations & Business Development at Abbott; 1993-1996 Product Manager at Eli Lilly.Past directorships expiring within the last five years .Outside of Sanofi group - Chairman of the Board of Directors of EnnoDC.

Carole Ferrand began her career in 1992 at PricewaterhouseCoopers, where she worked first in audit and then in financial consultancy. After ten years at Sony France, first as Chief Financial Officer (2000-2002) and then as General Secretary, she was appointed Chief Financial Officer of the EuropaCorp Group in 2011. In 2013, she was appointed Finance Director of the Artemis Group. She then served on the Board of Directors of Capgemini for two years (2016-2018) before being appointed to her current position as Group CFO. Carole Ferrand is a graduate of Ecole des Hautes Etudes Commerciales (HEC Paris). Directorships and appointments outside the Sanofi Group Directorships as of 12/31/2021 Fnac Darty (France): Independent director (until May 18, 2022); Chairwoman of the Audit Committee (until May 18, 2022).Past directorships expiring within the last five years OUTSIDE THE SANOFI GROUP In French companies Director and Chair of the Audit Committee of Fnac Darty Member of the Executive Committee of June 21 SASPresident of Capgemini Ventures SAS In foreign companies Substitute of Alain de Marcellus, Capgemini Brasil SA (Brazil)Director of Capgemini Solutions Canada Inc.Director of Capgemini UK plc Director of CGS Holdings Ltd (United Kingdom)Director of Capgemini Espana SL (Spain) Director of Altran Innovacion SLU (Spain).

Mr. John Sundy, Independent Director. Education and professional experience: B. S. in biology from Bucknell University; M.D. from Hahnemann University; Ph. D in immunology from Hahnemann University; Clinical training in rheumatology and allergy/immunology at Duke. Since 2022 Chief Medical Officer and Head of Research and Development at Seismic Therapeutic ; 2020-2021 Chief Medical Officer at Pandion Therapeutics; 2014-2020 Several management positions including Senior Vice President at Gilead Sciences; 2006-2014 Adjunct Professor of Medicine in the Division of Rheumatology and Immunology at Duke University School of Medicine.

Ms. Clotilde Delbos, Independent Director. Education and professional experience: Various positions at Renault Group * including Group Chief Financial Officer, Chairwoman of the Board of Directors of RCI Banque, Interim Chief Executive Officer of Renault SA, Deputy Chief Executive Officer of the Renault group and Chief Executive Officer of Mobilize 2021-22; Various positions in Internal Audit, Mergers & Acquisitions and Treasury, including at PricewaterhouseCoopers and Pechiney Before 2012.Past directorships expiring within the last five years OUTSIDE THE SANOFI GROUP None In French companies President of RCI Banque SA President of Renault Venture Capital President of Renault Mobility as an Industry In foreign companies Director of Renault Espana.

Ms. Anne-Francoise Nesmes, Independent Director. Education and professional experience: 2020-2024 Chief Financial Officer of Smith + Nephew PLC; 2016-2020 Chief Financial Officer of Merlin Entertainments PLC; 2013-2016 Chief Financial Officer of Dechra Pharmaceuticals PLC; 1997-2013 Various finance positions at GlaxoSmithKline PLC * including Senior Vice President of Finance for global vaccines.

Barbara Lavernos has spent her entire career with L'Oreal, whom she joined in 1991. In 2004, she was appointed Global Chief Procurement Officer, and was Managing Director of Travel Retail in 2011. In 2014, she was appointed Executive Vice-President Operations and became a member of the L'Oreal group Executive Committee. Since the end of 2018, she becomes Chief Technology and Operations Officer at L'Oreal. Since February 2021, she is President of Research, Innovation and Technologies and in May 2021, she was appointed Deputy CEO of L'Oreal. Barbara Lavernos is a graduate of the HEI chemical engineering school at Lille (France). In December 2020, she was named Chevalier of the Legion of Honor.Past directorships expiring within the last five years In foreign companies L'Oreal Group: Board member of Lactobio A/S (Denmark) Board member of Bak Skincare ApS (Denmark).

On November 19, 2018 Christophe Babule has been appointed Executive Vice-President, Chief Financial Officer and member of L'Oreal's Executive Committee as of mid-February 2019. Christophe Babule has spent his career with L'Oreal, which he joined in 1988. He spent 7 years in the Luxury Division in Italy before being appointed as Director of Administration & Finance based in China. In 2007, he was appointed Administration & Financial Director for Mexico. In 2010, he returned to France to join Christian Mulliez's Executive Committee as Director of Internal Audit for nearly 5 years. Afterwards he was appointed to the position of Administration & Financial Director for the Asia Pacific Zone based in Shanghai and then in Hong Kong. Christophe Babule is a graduate of HEC (Ecole des Hautes Etudes Commerciales) Paris and holds a Master of Business Administration (MBA) in finance. Directorships and appointments outside the Sanofi Group: Directorships as of 12/31/2021 L'Oreal Group: Director of L'Oreal USA Inc. (United States); Director of the L'Oreal pour les femmes Foundation (France)

Rachel Duan joined GE in 1996 and worked at GE across multiple businesses in the US, Japan and China. Since 2006, she has held senior leadership positions including CEO of GE Advanced Materials China and then Asia Pacific, CEO of GE Healthcare China, and CEO of GE China. Most recently, Rachel Duan served as President & CEO of GE's Global Markets where she was responsible for driving GE's growth in global emerging markets including China, APAC, India, Africa, Middle East and Latin America. Rachel Duan also serves as non-executive board member of AXA S.A. A native of Shanghai, Rachel Duan holds a bachelor's degree in Economics and International Business from Shanghai International Studies University, China and an MBA from The University of Wisconsin - Madison, USA.Directorships and appointments outside the Sanofi Group Directorships as of 12/31/2021 Independent director of AXA (France) Independent director of HSBC Independent director of Adecco Group.Since March 2024 Independent Director, Kering.

Wolfgang Laux works for Sanofi and Aventis since 2000. Since 2025 Product Launch Manager at Sanofi Winthrop Industries, Gentilly (France).Until 2006 he worked as Senior Scientist in Process Development in Frankfurt/Hochst and since 2006 as Industrialization Coordinator for new products in Manufacturing and Supply's central organization at Croix-de-Berny and Gentilly. Involved in employee representation since 2014 for the trade union organization CFE-CGC, he has been a member of the Works council of the Sanofi Chimie central organization (since 2014), member of the Committee on hygiene, safety and working conditions (CHSCT, 2016-2019) and trade union delegate (since 2016). Wolfgang Laux holds a Ph.D. in organic chemistry from the University of Frankfurt am Main and has been a post-doctoral research fellow at the State University of New York at Stony Brook (US, 1998-2000) and at the University of Montpellier (France, 1996-1997). He holds a Corporate Director's Certificate from SciencesPo / IFA (Certificat Administrateur de Societes).

Humberto de Sousa joined the Board on April 30, 2025.Education and professional experience STI Baccalaureate (Baccalaureat STI) in Electrical Engineering Since 2018 Group Maintenance Coordinator, Sanofi Group; 2013-2025 Employee representative, CFDT Union; 2007-2018 Maintenance/Service technician, Sanofi Group; 1999-2000 Maintenance/Service technician, Rhone Poulenc.

Paul Hudson joined Sanofi as Chief Executive Officer on September 1, 2019.Previously CEO of Novartis Pharmaceuticals (2016-2019), where he was a member of the Executive Committee, Paul has had an extensive international career in healthcare that spans the US, Japan and Europe.Prior to Novartis, he worked for AstraZeneca, where he held several increasingly senior positions and most recently carried out the roles of President, AstraZeneca United States and Executive Vice President, North America.He began his career in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synthelabo UK.Paul holds a degree in economics from Manchester Metropolitan University in the UK and in 2018, his alma mater awarded him an honorary Doctor of Business Administration for his achievements in the pharmaceutical industry. He also holds a diploma in marketing from the Chartered Institute of Marketing, also in the UK.

Manuela Buxo will be appointed as Executive Vice President, Specialty Care effective from March 1, 2026.Manuela Buxo is a global healthcare executive with over 25 years of experience driving growth, transformation and innovation across Specialty Care and Consumer Health. Across an international career spanning 6 countries, she has held leadership roles of increasing responsibility at Bayer and Sanofi at country, regional, and global levels.Since 2023, she has served as Global Head of Immunology Alliance, overseeing Dupixent and Kevzara. She joined Sanofi in 2014 as Vice President of Global Categories & Innovation for the Consumer Health division. In 2017, she was appointed Senior Vice President, Global Strategic Marketing, before taking on responsibility for Region Europe in the Specialty Care Global Business Unit in 2020, which included therapeutic areas such as immunology, neurology, oncology, rare diseases, and rare blood disorders.She graduated from HHL Leipzig Graduate School of Management and holds an undergraduate degree from Friedrich Schiller University Jena.Manuela Buxo is a citizen of Germany.

Audrey Duval joined Sanofi in September 2022 as President, Sanofi France.Audrey began her career in public hospitals in Paris and went on to work as a Researcher at the Pasteur Research Center of Hong Kong University and then as a Scientific Expert at Salusmed, based in Hong Kong. She later returned to France to join Pfizer, working in medical affairs in the areas of Endocrinology, Transplant and Rheumatology, and continues to retain that role, supporting and coordinating Sanofi's representation to its various external stakeholders in France. Prior to joining Sanofi, Audrey worked for Novartis, where she served as Business Franchise Head for Ophthalmology and then Country President for the company's operations in Ireland.Audrey holds a Medical Doctorate from the Paris Faculty of Medicine Cochin, and a Bachelor of Science in Medical Biology.Audrey Duval is a citizen of France.

Mr. Frederic Oudea, Since 2023 Sanofi :Chairman of the Board of Directors of Sanofi (May 2023) Senior Executive Advisor of Bruxelles Lambert Group (November 2023) 1995-2023 Societe Generale :Chief Executive Officer of Societe Generale (2015-2023) Chief Executive Officer and Chairman of the Board of Societe Generale (2009-2015) Chief Executive Officer of Societe Generale (2008-2009)Group Chief Financial Officer of Societe Generale (2003-2008)Deputy Group Chief Financial Officer of Societe Generale (2002-2003)Head of global supervision and development of the Equity Department of Societe Generale (1998-2002)Assistant Manager, then Manager of the Corporate Banking department in London at Societe Generale (1995-1998) Education and professional experience Graduate of ENA (ecole Nationale d'Administration) Degree from ecole Polytechnique.Past directorships expiring within the last five years - Board member of ALD Automotive.

Thomas Triomphe joined Vaccines in 2004 and has since advanced within the company in several roles of increasing responsibility in sales and marketing at country, regional and global levels. From 2015 to 2018, he was Head of the Asia-Pacific Region, based in Singapore. Before that, he served as Head of Vaccines Japan from 2012 to 2015. In 2010, he became Associate Vice President, Head of the Influenza-Pneumo Franchise after three years as Director for the same franchise, based in the United States. Earlier in his career, Thomas worked in banking and strategic consulting.Thomas served as Vice President and Head of Franchise & Product Strategy for Vaccines from January 2018, in which position he implemented the strategy for our vaccine franchises, in close collaboration with Manufacturing & Supply and R&D.He was appointed to his current position on June 15, 2020.Thomas earned his MSc in industrial engineering from Ecole des Ponts ParisTech and the IFP School, and he also holds an MBA from INSEAD.Thomas Triomphe is a citizen of France.

Madeleine Roach joined Sanofi in 2022 as Head of Internal Audit and Risk Management, before being appointed to the Executive Committee on October 1, 2023.Prior to joining Sanofi, Madeleine served at AstraZeneca as Head of Group Finance Services, Asia-Pacific and Head of Global Business Services Site Lead in Malaysia, delivering a wide range of business services to stakeholders and further expanding the site with the addition of value-added services and digitalization capabilities, whilst attracting top talent through strong employer branding.Madeleine also held positions of growing responsibility in Finance and Global Business Services at AstraZeneca, after starting her career at PricewaterhouseCoopers and KPMG in Assurance and Advisory services, in Germany and the UK.Madeleine holds a BA (Hons) in Economics and Politics from the School of Oriental and African Studies, University of London.Madeleine Roach is a citizen of Germany.

Houman Ashrafian joined Sanofi on September 11, 2023.Houman joined Sanofi from SV Health Investors where he was Managing Partner of the global private equity and venture capital investment platform which has a special focus on biotechnology, healthcare growth equity, and medtech. He has a robust track record in building high value, successful companies in the healthcare space, that brought transformational medicines from discovery to market: he co-founded and chaired the biotech companies Alchemab Therapeutics, Dualitas, Enara Bio, Mestag Therapeutics, Sitryx and Trex Bio. Previously, he was Vice President and head of the Clinical Science Group at UCB with a main focus on precision medicine strategies and early clinical activities across the R&D portfolio. He also co-founded Cardiac Report, a cardiac services company, Heart Metabolics, Catamaran Bio, as well as Weatherden, a boutique clinical consultancy.Houman is an Honorary Consultant Cardiologist at the John Radcliffe Hospital in Oxford, and a Visiting Professor at the University of Oxford in the UK. He has received numerous prestigious awards and recognitions over the course of his career, including the Michael Davies Early Career Award from the British Cardiovascular Society and the Schuldham Prize.Houman has a bachelor's and master's degree from the University of Cambridge (UK) and a BM BCh and DPhil from the University of Oxford (UK).Houman Ashrafian is a citizen of the United Kingdom.

From 1989 to 1994, Olivier Charmeil worked in the Mergers & Acquisitions department of Banque de l'Union Europeenne. He joined Sanofi Pharma in 1994 as head of Business Development. Subsequently, he held various positions within Sanofi, including Chief Financial Officer (Asia) of Sanofi-Synthelabo in 1999 and Attache to the Chairman, Jean-Francois Dehecq, in 2000, before being appointed as Vice President, Development within the Sanofi-Synthelabo International Operations Directorate, where he was responsible for China and support functions. In 2003, Olivier Charmeil was appointed Chairman and Chief Executive Officer of Sanofi-Synthelabo France, before taking the position of Senior Vice President, Business Management and Support, Pharmaceutical Operations. In this role, he piloted the operational integration of Sanofi-Synthelabo and Aventis. He was appointed Senior Vice President Asia/Pacific, Pharmaceutical Operations in February 2006; Operations Japan reported to him from January 1, 2008, as did Asia/Pacific and Japan Vaccines from February 2009. On January 1, 2011, Olivier Charmeil was appointed Executive Vice President Vaccines, and joined our Executive Committee.In May 2015, Olivier Charmeil and Andre Syrota were appointed as Co-Leaders of Medicine of the Future, an initiative developed by the French Minister for Economy, Industry and Digital Affairs, the French Minister for Social Affairs, Health and Women's Rights and the French Minister for National and Higher Education and Research. They have been tasked with assembling a group of industrialists and academics, with the objective of imagining how French industry can accelerate the launch and export of innovative industrial products, with an emphasis on new biotechnologies.From June 2016 to December 2018, Olivier Charmeil served as Executive Vice President of our General Medicines and Emerging Markets Global Business Unit. He took up the position of Executive Vice President China & Emerging Markets in January 2019. In February 2020 he was appointed to lead the General Medicines GBU, created out of the former Primary Care and China & Emerging Markets GBUs. He also serves as sponsor for China. Also in 2020, Olivier became a Board Member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).Olivier is a graduate of HEC (Ecole des Hautes Etudes Commerciales) and of the Institut d'Etudes Politiques in Paris.Olivier Charmeil is a citizen of France.

Natalie Bickford joined Sanofi on August 1, 2020. She has worked in HR for more than 20 years and brings a wealth of experience in consumer-facing industries to Sanofi.Prior to joining Sanofi, Natalie was Group HR Director at Merlin Entertainments, the world's second largest location-based entertainment business, where she was responsible for 30,000 employees across Europe, North America, and Asia Pacific. She also held senior HR positions at Sodexo, AstraZeneca and Kingfisher Plc.Natalie has a strong track record of transforming organizations, with a strong focus on inclusion and diversity. She was awarded HR Diversity Champion of the Year at the European Diversity Awards in November 2019. Natalie is also Board member of the Kronos Workforce Institute, a reflection of her deep interest in understanding and shaping the future of work. Natalie is a Board Advisor to the Coalition for Epidemic Preparedness Innovation (CEPI).Natalie holds a degree in French and International Politics from the University of Warwick in the UK.Natalie Bickford is a citizen of the United Kingdom.

Roy Papatheodorou leads the Legal, Ethics and Business Integrity and Global Security (LEBI & GS) team. The LEBI & GS team is composed of lawyers, patent attorneys, compliance officers and security professionals covering Sanofi's operations around the world. Its team members play an essential role in protecting the interests of the company and of its patients, customers, shareholders, and employees while delivering on Sanofi's strategy and contributing to its long-term ambition to transform the practice of medicine.Before joining Sanofi, Roy served as General Counsel of Novartis Pharmaceuticals from 2017. Prior to that, he headed up Legal Transactions at Novartis covering mergers & acquisitions, business development & licensing, antitrust, corporate & finance law, and venture funds.From 2011 to 2013, he was Group General Counsel and Secretary to the Board of Directors at Actavis, a leading global generic pharmaceuticals company. Prior to this, Roy spent several years at Linklaters in London, Moscow and Sao Paulo, advising mainly on corporate law, international mergers & acquisitions, private equity, and restructurings.Roy completed a Legal Practice Course from BPP School of Law in London and holds an LLB in Law from King's College London. He is a qualified solicitor in England & Wales.Roy Papatheodorou is a citizen of Cyprus and Italy.

Emmanuel Frenehard joined Sanofi in 2020 as Global Head of Digital, and was appointed to the Executive Committee on August 31, 2023.Prior to being appointed Chief Digital Officer, he held the positions of Global Head, Digital GBU teams and Digital Products. He also led the Sanofi Digital Accelerator and a number of digital commerce initiatives.Before joining Sanofi, Emmanuel spent 20 years leading large global organizations as well as three years in startups. He has built and launched multiple global digital products in support of existing and new business models. In particular, he managed iflix's rollout across Southeast Asia and led the launch of DisneyLife, Disney's direct-to-consumer digital subscription service, in the UK.Emmanuel is a graduate of the European Business School (EBS) and holds a Master II in Business, Finance and Audit from the Institut Superieur de Gestion (ISG).Emmanuel Frenehard is a citizen of France.

Brendan O'Callaghan joined Sanofi on January 1, 2015. He joined the Executive Committee on October 1, 2021.Brendan joined Sanofi in 2015 and was previously Global Head of Biologics and Industrial Affairs Head of the Specialty Care portfolio. He has played a key role in supporting our transformation to a fully integrated BioPharmaceutical company and advancing the digital transformation of our manufacturing network.Prior to Sanofi, Brendan worked at Schering-Plough before moving to Merck & Co. Inc./MSD as Head of Biologics and later Vice President of its Europe, Middle East and Africa Operations.Brendan graduated in chemical engineering from the University College of Dublin, where he currently serves as an honorary adjunct Professor of Chemical and Biochemical Engineering.Brendan O'Callaghan is a citizen of Ireland.

Francois Roger has served as Chief Financial Officer of Sanofi since April 2024, leading a team that manages financial risk and capital allocation to create value and growth for Sanofi.Francois joined Sanofi from Nestle where he was CFO for nearly nine years. Before Nestle, he served from 2013 to 2015 as CFO of Takeda Pharmaceuticals, based in Japan. He spent the first 14 years of his career working in the pharmaceutical industry, first at Roussel, Hoechst and later Aventis, serving in various countries. He worked at Danone from 2000 to 2008 in various finance roles and was CFO of Millicom, a NASDAQ listed, global mobile phone operator from 2008 to 2013. He has lived and worked in Europe, the United States, Asia, Africa and Latin America.Francois holds an MBA from Ohio State University in the US and a Major in Accounting from Audencia Business School in France.Francois Roger is a citizen of France.